☰

Jennifer R. Grandis - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Pathology, Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

383 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Qin B, Chen X, Zhu J, Kopechek J, Helfield B, Yu F, Cyriac J, Lavery L, Grandis JR, Villanueva FS. Ultrasound enhanced siRNA delivery using cationic liposome-microbubble complexes for the treatment of squamous cell carcinoma. Nanotheranostics. 8: 285-297. PMID 38577322 DOI: 10.7150/ntno.90516  0.302
2023 Lee RH, Johnson DE, Grandis JR. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer. Cancer Research. 83: 3162-3164. PMID 37779427 DOI: 10.1158/0008-5472.CAN-23-1858  0.307
2023 Jagadeeshan S, Prasad M, Badarni M, Ben Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, ... ... Grandis JR, et al. Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer. Cancer Research. PMID 36753744 DOI: 10.1158/0008-5472.CAN-22-2586  0.348
2022 Long Z, Grandis JR, Johnson DE. Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opinion On Emerging Drugs. 1-12. PMID 36131561 DOI: 10.1080/14728214.2022.2125954  0.379
2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, ... ... Grandis JR, et al. Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3187. PMID 36052496 DOI: 10.1158/0008-5472.CAN-22-1308  0.792
2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, ... ... Grandis JR, et al. Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3188. PMID 36052495 DOI: 10.1158/0008-5472.CAN-22-1307  0.792
2022 Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim MO, Ryan WR, Ha PK, Bauman JE, Wang SJ, Long SR, Johnson DE, Grandis JR. STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35929989 DOI: 10.1158/1078-0432.CCR-22-0744  0.399
2022 Li H, Peyser ND, Zeng Y, Ha PK, Johnson DE, Grandis JR. NSAIDs Overcome Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers. 14. PMID 35158773 DOI: 10.3390/cancers14030506  0.398
2021 Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O'Keefe R, Jin N, VanLandingham NK, ... ... Grandis JR, et al. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science (New York, N.Y.). 374: eabf2911. PMID 34591642 DOI: 10.1126/science.abf2911  0.642
2021 Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, ... ... Grandis JR, et al. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Jci Insight. PMID 34546978 DOI: 10.1172/jci.insight.151982  0.704
2021 Bhola NE, Njatcha C, Hu L, Lee ED, Shiah JV, Kim MO, Johnson DE, Grandis JR. PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head & Neck. PMID 34346116 DOI: 10.1002/hed.26827  0.684
2021 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4129. PMID 34261774 DOI: 10.1158/1078-0432.CCR-21-2141  0.694
2021 Badarni M, Prasad M, Golden A, Bhattacharya B, Levin L, Yegodayev KM, Dimitstein O, Joshua BZ, Cohen L, Khrameeva E, Kong D, Porgador A, Braiman A, Grandis JR, Rotblat B, et al. IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer. Cancers. 13. PMID 34067117 DOI: 10.3390/cancers13092250  0.381
2021 Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34045293 DOI: 10.1158/1078-0432.CCR-21-1259  0.319
2021 Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nature Communications. 12: 2383. PMID 33888713 DOI: 10.1038/s41467-021-22619-w  0.392
2020 Qureshy Z, Johnson DE, Grandis JR. Targeting the JAK/STAT pathway in solid tumors. Journal of Cancer Metastasis and Treatment. 6. PMID 33521321 DOI: 10.20517/2394-4722.2020.58  0.434
2020 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nature Reviews. Disease Primers. 6: 92. PMID 33243986 DOI: 10.1038/s41572-020-00224-3  0.315
2020 Shiah JV, Grandis JR, Johnson DE. Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides. Molecular Cancer Therapeutics. PMID 33203730 DOI: 10.1158/1535-7163.MCT-20-0599  0.304
2020 Cui Z, Kang H, Grandis JR, Johnson DE. CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers. Molecular Cancer Research : McR. PMID 32883697 DOI: 10.1158/1541-7786.Mcr-20-0565  0.441
2020 Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, Gaither-Davis A, Grandis JR, Stabile LP. Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers. 12. PMID 32545260 DOI: 10.3390/Cancers12061537  0.428
2020 Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS. Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer. Molecular Cancer Therapeutics. PMID 32430488 DOI: 10.1158/1535-7163.Mct-19-1036  0.46
2020 Ngan HL, Liu Y, Fong AY, Poon PHY, Yeung CK, Chan SSM, Lau A, Piao W, Li H, Tse JSW, Lo KW, Chan SM, Su YX, Chan JYK, Lau CW, ... ... Grandis JR, et al. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Science Alliance. 3. PMID 32381551 DOI: 10.26508/lsa.201900545  0.313
2020 Lee M, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochimica Et Biophysica Acta. Molecular Cell Research. 118679. PMID 32061630 DOI: 10.1016/J.Bbamcr.2020.118679  0.438
2020 O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. Plos One. 15: e0227261. PMID 31914141 DOI: 10.1371/Journal.Pone.0227261  0.7
2020 Cui Z, Tal H, Grandis J, Johnson D. HNSCC-associated CASP8 mutations promote resistance to apoptosis and mediate induction of immunosuppressive cytokines International Journal of Radiation Oncology*Biology*Physics. 106: 1222. DOI: 10.1016/J.Ijrobp.2020.02.005  0.326
2019 Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Molecular Medicine Reports. PMID 31661135 DOI: 10.3892/Mmr.2019.10766  0.452
2019 Cai Y, Yousef A, Grandis JR, Johnson DE. NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Advances in Biological Regulation. 100653. PMID 31594701 DOI: 10.1016/J.Jbior.2019.100653  0.436
2019 Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV and HPV head and neck squamous cell carcinoma to cisplatin. Oral Oncology. 95: 35-42. PMID 31345392 DOI: 10.1016/J.Oraloncology.2019.05.028  0.718
2019 Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31308059 DOI: 10.1158/1078-0432.Ccr-18-3453  0.4
2019 Meister KS, Godse NR, Khan NI, Hedberg ML, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR, Duvvuri U. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Scientific Reports. 9: 9130. PMID 31235758 DOI: 10.1038/S41598-019-45589-Y  0.513
2019 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Research. 79: 875. PMID 30770370 DOI: 10.1158/0008-5472.CAN-18-4087  0.655
2019 Sola AM, Johnson DE, Grandis JR. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion On Investigational Drugs. PMID 30753792 DOI: 10.1080/13543784.2019.1581172  0.447
2019 Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, ... ... Grandis JR, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. The Journal of Experimental Medicine. PMID 30683736 DOI: 10.1084/Jem.20181936  0.684
2019 Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene. PMID 30647454 DOI: 10.1038/S41388-018-0657-6  0.388
2019 Cui Z, Tal H, Grandis JR, Johnson DE. Abstract 726: HNSCC-associated caspase-8 mutations mediate resistance to apoptosis and up-regulation of immunosuppressive cytokines Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-726  0.319
2018 Zhang L, Li Z, Liu Y, Xu S, Tandon M, Appelboom B, LaValle CR, Chiosea SI, Wang L, Sen M, Lui VWY, Grandis JR, Wang QJ. Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. Bmc Cancer. 18: 1107. PMID 30419840 DOI: 10.1186/S12885-018-4965-6  0.453
2018 Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. PMID 30390071 DOI: 10.1038/S41388-018-0537-0  0.406
2018 Lee YS, Johnson DE, Grandis JR. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion On Emerging Drugs. PMID 30376740 DOI: 10.1080/14728214.2018.1543400  0.421
2018 Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Cancer. PMID 30291796 DOI: 10.1002/Cncr.31651  0.481
2018 Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, et al. Multiple Routes to Oncogenesis are Promoted by the Human Papillomavirus-Host Protein Network. Cancer Discovery. PMID 30209081 DOI: 10.1158/2159-8290.Cd-17-1018  0.35
2018 Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics. PMID 29891486 DOI: 10.1158/1535-7163.Mct-17-1194  0.463
2018 Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. International Journal of Molecular Sciences. 19. PMID 29848966 DOI: 10.3390/Ijms19061608  0.355
2018 Leonard B, Brand TM, O'Keefe RA, Lee E, Zang Y, Kemmer JD, Li H, Grandis JR, Bhola NE. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research. PMID 29792310 DOI: 10.1158/0008-5472.Can-18-0459  0.741
2018 Santuray RT, Johnson DE, Grandis JR. New Therapies in Head and Neck Cancer. Trends in Cancer. 4: 385-396. PMID 29709262 DOI: 10.1016/J.Trecan.2018.03.006  0.436
2018 Brand TM, Hartmann S, Bhola NE, Li H, Zang Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, ... ... Grandis JR, et al. Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Research. PMID 29440171 DOI: 10.1158/0008-5472.Can-17-1672  0.813
2018 Kemmer JD, Johnson DE, Grandis JR. Leveraging Genomics for Head and Neck Cancer Treatment. Journal of Dental Research. 22034518756352. PMID 29420101 DOI: 10.1177/0022034518756352  0.418
2018 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews. Clinical Oncology. PMID 29405201 DOI: 10.1038/Nrclinonc.2018.8  0.373
2018 Cho J, Johnson DE, Grandis JR. Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology. 28: 2-11. PMID 29173752 DOI: 10.1016/J.Semradonc.2017.08.005  0.418
2018 Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Grandis JR. High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods in Molecular Biology (Clifton, N.J.). 1683: 229-244. PMID 29082496 DOI: 10.1007/978-1-4939-7357-6_14  0.373
2018 Duvvuri U, George J, Kim S, Alvarado D, Neumeister V, Chenna A, Hawthorne T, LaVallee T, Grandis JR, Bauman JE. Abstract CT058: Molecular and clinical activity of CDX-3379, an anti-ErbB3 monoclonal antibody, in head and neck squamous cell carcinoma: A preoperative "window of opportunity" study Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct058  0.42
2018 Ngan H, Fong AY, Chan S, Yu SC, Ip LRH, Grandis JR, Lui V. Abstract 4278: Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC) Cancer Research. 78: 4278-4278. DOI: 10.1158/1538-7445.Am2018-4278  0.369
2018 O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Abstract 1972: Targeting the IL-6 signaling pathway overcomes cetuximab resistance in head and neck squamous cell carcinoma Cancer Research. 78: 1972-1972. DOI: 10.1158/1538-7445.Am2018-1972  0.394
2017 Zhong Q, Liu Z, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, ... ... Grandis JR, et al. The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29133573 DOI: 10.1158/1078-0432.Ccr-17-0352  0.439
2017 Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, ... ... Grandis JR, et al. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head & Neck. PMID 28945296 DOI: 10.1002/Hed.24911  0.335
2017 Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Reviews. PMID 28866730 DOI: 10.1007/S10555-017-9687-8  0.495
2017 Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. Journal of Chemical Biology. 10: 129-141. PMID 28684999 DOI: 10.1007/S12154-017-0169-9  0.34
2017 Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine. 9. PMID 28566428 DOI: 10.1126/Scitranslmed.Aal5148  0.694
2017 Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncology. 69: 38-45. PMID 28559019 DOI: 10.1016/J.Oraloncology.2017.03.011  0.51
2017 Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, ... ... Grandis JR, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. Jci Insight. 2: e90449. PMID 28352657 DOI: 10.1172/Jci.Insight.90449  0.499
2017 Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U. TMEM16A/ANO1 Suppression Improves Response to Antibody Mediated Targeted Therapy of EGFR and HER2/ERBB2. Genes, Chromosomes & Cancer. PMID 28177558 DOI: 10.1002/Gcc.22450  0.484
2017 Ben-Dayan MM, Ow TJ, Belbin TJ, Wetzler J, Smith RV, Childs G, Diergaarde B, Hayes DN, Grandis JR, Prystowsky MB, Schlecht NF. Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. Cancer Medicine. PMID 28102032 DOI: 10.1002/Cam4.961  0.36
2017 Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, ... ... Grandis JR, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications. 8: 14121. PMID 28098136 DOI: 10.1038/Ncomms14121  0.345
2017 Peyser ND, Grandis JR. Cancer genomics: Spot the difference. Nature. PMID 28052059 DOI: 10.1038/Nature21112  0.326
2017 Bauman JE, Duvvuri U, Ferris RL, Ohr J, Gooding WE, Kim S, Johnson JT, Grandis JR, Stabile LP. Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 35: 6038-6038. DOI: 10.1200/Jco.2017.35.15_Suppl.6038  0.353
2017 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe R, Ranall MV, Bandyopadhyay S, Soucheray M, Swaney DL, Krogan N, Kemp C, Duvvuri U, Johnson DE, Ozbun MA, ... ... Grandis JR, et al. Abstract PR04: HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Aacrahns17-Pr04  0.708
2017 Grandis JR. Abstract IA09: Comprehensive genomic characterization of head and neck squamous cell carcinomas Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Aacrahns17-Ia09  0.398
2017 Brand T, Zeng Y, Leonard B, Keefe RO, Li H, Johnson D, Grandis J, Bhola NE. Abstract 95: Targeting BRD4 overcomes cetuximab resistance in HNSCC Cancer Research. 77: 95-95. DOI: 10.1158/1538-7445.Am2017-95  0.33
2017 O'Keefe RA, Bhola N, Brand TM, Zeng Y, Johnson DE, Grandis JR. Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma Cancer Research. 77: 4108-4108. DOI: 10.1158/1538-7445.Am2017-4108  0.717
2017 Njatcha C, Farooqui M, Grandis JR, Siegfried JM. Abstract 4101: Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy Cancer Research. 77: 4101-4101. DOI: 10.1158/1538-7445.Am2017-4101  0.486
2017 Hedberg ML, Peyser N, Gooding W, Li H, Brand T, Olivas V, Bivona T, Choisea S, Wang L, Johnson J, Duvvuri U, Ferris R, Johnson D, Ha P, Bauman J, ... Grandis J, et al. Abstract 1779: Chronic NSAID use increases survival inPIK3CA-altered head and neck squamous cell carcinoma Cancer Research. 77: 1779-1779. DOI: 10.1158/1538-7445.Am2017-1779  0.434
2016 Grandis JR, Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE. Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27986750 DOI: 10.1158/1078-0432.Ccr-16-2203  0.701
2016 Algazi AP, Grandis JR. Head and neck cancer in 2016: A watershed year for improvements in treatment? Nature Reviews. Clinical Oncology. PMID 27922045 DOI: 10.1038/Nrclinonc.2016.196  0.339
2016 Bhola NE, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Annals of Translational Medicine. 4: S57. PMID 27868025 DOI: 10.21037/Atm.2016.10.51  0.697
2016 Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. Plos One. 11: e0166185. PMID 27855189 DOI: 10.1371/Journal.Pone.0166185  0.405
2016 Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL. Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemotherapy and Pharmacology. PMID 27778071 DOI: 10.1007/S00280-016-3181-9  0.406
2016 Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, ... ... Grandis JR, et al. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nature Genetics. PMID 27749845 DOI: 10.1038/Ng.3685  0.303
2016 Hartmann S, Grandis JR. Treatment of head and neck cancer in the elderly. Expert Opinion On Pharmacotherapy. 17: 1903-21. PMID 27643444 DOI: 10.1080/14656566.2016.1220540  0.388
2016 LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, et al. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 27381083 DOI: 10.1016/J.Bmcl.2016.06.017  0.319
2016 Hartmann S, Bhola NE, Grandis JR. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27370607 DOI: 10.1158/1078-0432.Ccr-16-0951  0.769
2016 Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27370606 DOI: 10.1158/1078-0432.Ccr-16-0292  0.475
2016 Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research (Philadelphia, Pa.). PMID 27339168 DOI: 10.1158/1940-6207.Capr-15-0290  0.443
2016 Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman SM, et al. The non-coding landscape of head and neck squamous cell carcinoma. Oncotarget. PMID 27323410 DOI: 10.18632/Oncotarget.9979  0.371
2016 Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino ML, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a chemoprevention target in carcinogen-induced head and neck squamous cell carcinoma. Cancer Prevention Research (Philadelphia, Pa.). PMID 27267892 DOI: 10.1158/1940-6207.Capr-16-0089  0.48
2016 Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head & Neck. PMID 27232378 DOI: 10.1002/Hed.24501  0.445
2016 Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulo M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, et al. Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locoregionally-advanced head and neck cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27177865 DOI: 10.1093/Annonc/Mdw204  0.406
2016 Grandis J. HER2 and HER3 in HPV+ and HPV- HNSCC-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1826. PMID 27037255 DOI: 10.1158/1078-0432.Ccr-15-3100  0.346
2016 Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal of Clinical Investigation. 126: 1606. PMID 27035818 DOI: 10.1172/Jci86862  0.317
2016 Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, ... ... Grandis JR, et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. PMID 27034009 DOI: 10.18632/Oncotarget.8448  0.389
2016 Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget. PMID 27004400 DOI: 10.18632/Oncotarget.8188  0.507
2016 Stabile LP, Egloff AM, Zhou P, Gooding WE, Grandis JR, Bauman JE. Abstract CT119: Phase II study of dasatinib in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct119  0.442
2016 Peyser ND, Wang L, Acquafondata M, Freilino M, Li H, Zeng Y, Sen M, Gooding WE, Johnson DE, Grandis JR. Abstract 5243: STAT3 inhibition as chemoprevention in a chemically induced mouse model of HNSCC Cancer Research. 76: 5243-5243. DOI: 10.1158/1538-7445.Am2016-5243  0.404
2016 Khan N, Davis KS, Godse N, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Grandis JR, Duvvuri U. Abstract 2979: Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC Cancer Research. 76: 2979-2979. DOI: 10.1158/1538-7445.Am2016-2979  0.525
2016 Brand TM, Hartmann S, Bhola N, Peyser ND, Li H, Zeng Y, Randall MV, Bandyopadhyay S, Grandis JR. Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer Cancer Research. 76: 1205-1205. DOI: 10.1158/1538-7445.Am2016-1205  0.723
2016 Geiger J, Egloff A, Ohr J, Stabile L, Gooding W, Flaherty J, Gibson M, Grandis J, Bauman J. Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) International Journal of Radiation Oncology*Biology*Physics. 94: 930. DOI: 10.1016/J.Ijrobp.2015.12.242  0.36
2015 Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncology. PMID 26733183 DOI: 10.1016/J.Oraloncology.2015.11.022  0.54
2015 Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, et al. Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. Oral Oncology. PMID 26686755 DOI: 10.1016/J.Oraloncology.2015.11.016  0.43
2015 Li H, Wheeler S, Park YS, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Molecular Cancer Research : McR. PMID 26685214 DOI: 10.1158/1541-7786.Mcr-15-0354  0.41
2015 Kopechek JA, Carson AR, McTiernan CF, Chen X, Hasjim B, Lavery L, Sen M, Grandis JR, Villanueva FS. Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth. Theranostics. 5: 1378-87. PMID 26681983 DOI: 10.7150/Thno.12822  0.406
2015 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population. Cancer Research. PMID 26676751 DOI: 10.1158/0008-5472.Can-15-1640-T  0.723
2015 Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal of Clinical Investigation. PMID 26619122 DOI: 10.1172/Jci82066  0.364
2015 Parsel SM, Grandis JR, Thomas SM. Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene. PMID 26592450 DOI: 10.1038/Onc.2015.424  0.455
2015 Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, ... ... Grandis JR, et al. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. The Journal of Clinical Investigation. PMID 26571401 DOI: 10.1172/Jci82826  0.424
2015 Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA. MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. Bmc Cancer. 15: 861. PMID 26545583 DOI: 10.1186/S12885-015-1888-3  0.342
2015 Bauman JE, Grandis J. Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection. Jama Oncology. 1-2. PMID 26540592 DOI: 10.1001/Jamaoncol.2015.4637  0.308
2015 Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annual Review of Medicine. PMID 26332002 DOI: 10.1146/Annurev-Med-051914-021907  0.36
2015 Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR. HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Assay and Drug Development Technologies. 13: 356-76. PMID 26317883 DOI: 10.1089/Adt.2015.663  0.365
2015 Peyser ND, Du Y, Li H, Lui V, Xiao X, Chan TA, Grandis JR. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. Plos One. 10: e0135750. PMID 26267899 DOI: 10.1371/Journal.Pone.0135750  0.445
2015 Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, ... ... Grandis JR, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34  0.469
2015 Pollock N, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave K, Li H, Zeng Y, Grandis JR. Increased expression of HER2, HER3, and HER2:HER3 heterodimers in HPV-positive HNSCC using a novel proximity-based assay: Implications for targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26138066 DOI: 10.1158/1078-0432.Ccr-14-3338  0.39
2015 Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. PMID 25982282 DOI: 10.1038/onc.2015.171  0.369
2015 Wen Y, Grandis JR. Emerging drugs for head and neck cancer. Expert Opinion On Emerging Drugs. 20: 313-29. PMID 25826749 DOI: 10.1517/14728214.2015.1031653  0.463
2015 Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia (New York, N.Y.). 17: 256-64. PMID 25810010 DOI: 10.1016/J.Neo.2015.01.003  0.53
2015 Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. Plos One. 10: e0117781. PMID 25658924 DOI: 10.1371/Journal.Pone.0117781  0.522
2015 Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discovery. 5: 239-44. PMID 25643909 DOI: 10.1158/2159-8290.Cd-14-1205  0.391
2015 Dixit R, Weissfeld JL, Wilson DO, Balogh P, Sufka P, Siegfried JM, Grandis JR, Diergaarde B. Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the Pittsburgh Lung Screening Study. Cancer. 121: 1431-5. PMID 25559556 DOI: 10.1002/Cncr.29189  0.366
2015 Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Letters. 357: 549-56. PMID 25511740 DOI: 10.1016/J.Canlet.2014.12.008  0.306
2015 Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 526-33. PMID 25424855 DOI: 10.1158/1078-0432.Ccr-14-1432  0.47
2015 Du Y, Grandis JR. Receptor-type protein tyrosine phosphatases in cancer. Chinese Journal of Cancer. 34: 61-9. PMID 25322863 DOI: 10.5732/Cjc.014.10146  0.432
2015 Bauman JE, Duvvuri U, Gooding WE, Clump DA, Karlovits BJ, Wehbe AM, Miller FR, Johnson JT, Ferris RL, Kim S, Heron DE, Ohr J, Grandis JR, Argiris A. Phase I study of cetuximab, intensity-modulated radiotherapy (C-IMRT), and intratumoral EGFR antisense (AS) DNA in patients with locally advanced head and neck cancer (HNC). Journal of Clinical Oncology. 33: 6074-6074. DOI: 10.1200/Jco.2015.33.15_Suppl.6074  0.36
2015 Sheth S, Weissfeld JL, Romkes M, Ferris RL, Grandis JR, Bauman JE, Diergaarde B. Germline variation in NFE2L2/CUL3/KEAP1 and risk of head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 33: 1540-1540. DOI: 10.1200/Jco.2015.33.15_Suppl.1540  0.338
2015 Zhou P, Li H, Wheeler S, Grandis JR, Stabile LA, Egloff AM. Abstract B39: Generation of head and neck cancer patient-derived xenografts with in vivo acquired cetuximab resistance Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B39  0.412
2015 Hedberg ML, Li H, Zeng Y, Grandis JR. Abstract A39: PI3K inhibition in preclinical models of HNSCC Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A39  0.469
2015 Bauman JE, Zang Y, Sen M, Normolle DP, Kensler TW, Trivedi S, Egner PA, Sheth SH, Grandis JR, Johnson DE. Abstract 894: Sulforaphane as a chemopreventive agent against oral carcinogenesis Cancer Research. 75: 894-894. DOI: 10.1158/1538-7445.Am2015-894  0.383
2015 Davis KS, Khan N, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Grandis JR, Duvvuri U. Abstract 1674: HER3 inhibition potentiates anti-tumor effects of PI3K inhibitors in pre-clinical models of HNSCC Cancer Research. 75: 1674-1674. DOI: 10.1158/1538-7445.Am2015-1674  0.361
2014 Peyser ND, Grandis JR. Genetic mutations in head and neck cancer: utilizing existing treatments. Pharmacogenomics. 15: 1553-5. PMID 25340729 DOI: 10.2217/Pgs.14.122  0.479
2014 Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, ... ... Grandis JR, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 111: 15544-9. PMID 25313082 DOI: 10.1073/Pnas.1416074111  0.365
2014 LaPorte MG, da Paz Lima DJ, Zhang F, Sen M, Grandis JR, Camarco D, Hua Y, Johnston PA, Lazo JS, Resnick LO, Wipf P, Huryn DM. 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorganic & Medicinal Chemistry Letters. 24: 5081-5. PMID 25288188 DOI: 10.1016/J.Bmcl.2014.09.001  0.363
2014 Nakajima EC, Laymon C, Oborski M, Hou W, Wang L, Grandis JR, Ferris RL, Mountz JM, Van Houten B. Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. Plos One. 9: e102452. PMID 25127378 DOI: 10.1371/Journal.Pone.0102452  0.311
2014 Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5041-51. PMID 25107914 DOI: 10.1158/1078-0432.Ccr-14-0051  0.384
2014 Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics. 46: 939-43. PMID 25086664 DOI: 10.1038/Ng.3051  0.383
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Grandis JR, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093  0.48
2014 Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE, Wagner J, Vernetti LA, Grandis JR, Lee AV, Stern AM, Schurdak ME, Taylor DL. Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. Plos One. 9: e102678. PMID 25036749 DOI: 10.1371/Journal.Pone.0102678  0.301
2014 Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, Grandis J, Gaither LA, Puthenveedu MA, Duvvuri U. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4673-88. PMID 24919570 DOI: 10.1158/1078-0432.Ccr-14-0363  0.731
2014 Bauman JE, Grandis JR. Targeting secondary immune responses to cetuximab: CD137 and the outside story Journal of Clinical Investigation. 124: 2371-2375. PMID 24837438 DOI: 10.1172/Jci76264  0.364
2014 Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Molecular Oncology. 8: 1220-30. PMID 24816188 DOI: 10.1016/J.Molonc.2014.03.018  0.445
2014 Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, ... ... Grandis JR, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3289-98. PMID 24727329 DOI: 10.1158/1078-0432.Ccr-13-3360  0.43
2014 Lei Y, Lui VW, Grandis JR, Egloff AM. Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma. Plos One. 9: e85619. PMID 24465623 DOI: 10.1371/Journal.Pone.0085619  0.378
2014 Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Molecular Cancer Research : McR. 12: 571-82. PMID 24425785 DOI: 10.1158/1541-7786.Mcr-13-0396  0.427
2014 Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S. STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. Plos One. 9: e81819. PMID 24404126 DOI: 10.1371/Journal.Pone.0081819  0.451
2014 Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, ... ... Grandis JR, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 1114-9. PMID 24395800 DOI: 10.1073/Pnas.1319551111  0.444
2014 Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Molecular Medicine (Cambridge, Mass.). 20: 46-56. PMID 24395569 DOI: 10.2119/Molmed.2013.00104  0.386
2014 Dʼsouza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999). 65: 603-10. PMID 24326607 DOI: 10.1097/Qai.0000000000000083  0.315
2014 Du Y, Peyser ND, Grandis JR. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacology & Therapeutics. 142: 88-98. PMID 24280066 DOI: 10.1016/J.Pharmthera.2013.11.007  0.459
2014 Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncology. 50: 120-7. PMID 24216166 DOI: 10.1016/J.Oraloncology.2013.10.013  0.409
2014 Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR. High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay and Drug Development Technologies. 12: 55-79. PMID 24127660 DOI: 10.1089/adt.2013.524  0.315
2014 Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, ... ... Grandis JR, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prevention Research (Philadelphia, Pa.). 7: 283-91. PMID 24085777 DOI: 10.1158/1940-6207.Capr-13-0215  0.396
2014 Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 33: 2846-56. PMID 23851501 DOI: 10.1038/Onc.2013.259  0.441
2014 Ferris RL, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Grandis J, Bauman JE, Gooding WE, Argiris A. Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC). Journal of Clinical Oncology. 32: 6090-6090. DOI: 10.1200/Jco.2014.32.15_Suppl.6090  0.402
2014 Bauman JE, Duvvuri U, Gooding WE, Gross ND, Song J, Yarbrough WG, Johnson FM, Wang L, Jimeno A, Sen M, Kass JI, Johnson JT, Ferris RL, Kim S, Rath TJ, ... ... Grandis JR, et al. Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 32: 6033-6033. DOI: 10.1200/Jco.2014.32.15_Suppl.6033  0.426
2014 Peyser ND, Wang L, Grandis JR. Abstract 5286: Promoter methylation of PTPRT provides a mechanism for STAT3 activation in HNSCC Cancer Research. 74: 5286-5286. DOI: 10.1158/1538-7445.Am2014-5286  0.393
2014 Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hoffree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Abstract 3821: A prognostic model of head and neck cancer ties TP53 mutation to 3p loss Cancer Research. 74: 3821-3821. DOI: 10.1158/1538-7445.Am2014-3821  0.408
2014 Vangara BS, Akhtar P, Grandis JR, Khan SA. Abstract 3557: Epigenetic modulation of microRNA-363 in human papillomavirus-positive head and neck squamous cell carcinoma Cancer Research. 74: 3557-3557. DOI: 10.1158/1538-7445.Am2014-3557  0.349
2014 Zumsteg Z, Morse N, Higginson D, Gupta G, Morris L, Ganly I, Grandis J, Lee N, Powell S, Scaltriti M, Baselga J. GDC-0032, A Novel p110α Inhibitor, Specifically Radiosensitizes Head and Neck Squamous Cell Carcinomas Harboring Activating PIK3CA Alterations International Journal of Radiation Oncology*Biology*Physics. 90: S37. DOI: 10.1016/J.Ijrobp.2014.05.152  0.443
2013 Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. Bmc Cancer. 13: 602. PMID 24341335 DOI: 10.1186/1471-2407-13-602  0.419
2013 Pendleton KP, Grandis JR. Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clinical Medicine Insights. Therapeutics. 2013. PMID 24273416 DOI: 10.4137/CMT.S10409  0.35
2013 Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM. Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. British Journal of Cancer. 109: 3049-56. PMID 24231953 DOI: 10.1038/Bjc.2013.624  0.411
2013 Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Oncotargets and Therapy. 6: 999-1010. PMID 23935373 DOI: 10.2147/Ott.S47903  0.428
2013 Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR. Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head and Neck Pathology. 7: 344-55. PMID 23645351 DOI: 10.1007/S12105-013-0447-Y  0.37
2013 Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, ... ... Grandis JR, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discovery. 3: 761-9. PMID 23619167 DOI: 10.1158/2159-8290.Cd-13-0103  0.41
2013 Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiology. 37: 505-11. PMID 23523331 DOI: 10.1016/J.Canep.2013.02.009  0.303
2013 Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, ... ... Grandis JR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1244-56. PMID 23422093 DOI: 10.1158/1078-0432.Ccr-12-3149  0.48
2013 Romick-Rosendale LE, Lui VW, Grandis JR, Wells SI. The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutation Research. 743: 78-88. PMID 23333482 DOI: 10.1016/J.Mrfmmm.2013.01.001  0.362
2013 Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 380-92. PMID 23213056 DOI: 10.1158/1078-0432.Ccr-12-1555  0.768
2013 Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SC, Contrucci S, Wang Y, Chiosea SI, Lathrop KL, Watkins S, Grandis JR, Armitage BA, et al. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. Acs Chemical Biology. 8: 345-52. PMID 23113581 DOI: 10.1021/Cb3003946  0.492
2013 Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 220-5. PMID 22898037 DOI: 10.1093/Annonc/Mds245  0.45
2013 Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR. Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head & Neck. 35: 270-9. PMID 22431275 DOI: 10.1002/Hed.22963  0.396
2013 Bauman JE, Gross ND, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea SI, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, ... ... Grandis JR, et al. Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 31: 6051-6051. DOI: 10.1200/Jco.2013.31.15_Suppl.6051  0.435
2013 Hayes DN, Grandis JR, El-Naggar AK. The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 31: 6009-6009. DOI: 10.1200/Jco.2013.31.15_Suppl.6009  0.428
2013 Sen M, Black J, Wheeler S, Freilino ML, Joyce S, Lui V, Zeng Y, Marshall K, Grandis JR. Abstract 4668: Antitumor efficacy of AZD1480 in head and neck squamous cell carcinoma. Cancer Research. 73: 4668-4668. DOI: 10.1158/1538-7445.Am2013-4668  0.5
2013 Lui VW, Allen EV, Li H, Zhang F, Zeng Y, Johnson JT, Garraway LA, Mills GB, Grandis JR. Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. Cancer Research. 73: 4565-4565. DOI: 10.1158/1538-7445.Am2013-4565  0.437
2013 Lui V, Peyser N, Ng PKS, Sen M, Li H, Zeng Y, Joyce S, Wang ZJ, Hammerman P, Mills G, Grandis JR. Abstract 4260: PTPRT mutation induces STAT3 activation in HNSCC preclinical models. Cancer Research. 73: 4260-4260. DOI: 10.1158/1538-7445.Am2013-4260  0.479
2013 Yazbeck VY, Dorritie K, Li C, Grandis J, Zang Y, Johnson DE. Abstract 2439: Obatoclax (GX15-070) potently induces apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines and enhances the activity of EGFR inhibitors. Cancer Research. 73: 2439-2439. DOI: 10.1158/1538-7445.Am2013-2439  0.496
2013 Hedberg ML, Lui V, Li H, Vangara B, Pendleton K, Zeng Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Diergaarde B, Hammerman P, Garraway L, Mills G, Grandis J. Abstract 2011: The PI3K pathway is the most frequently mutated mitogenic pathway in HNSCC. Cancer Research. 73: 2011-2011. DOI: 10.1158/1538-7445.Am2013-2011  0.396
2013 Fung C, Trent K, Joyce S, Zhou P, Nukui T, Weeks DE, Diergaarde B, Ye Y, Wu X, Yuan J, Grandis J, Weissfeld JL, Romkes M, Egloff AM. Abstract 1340: Identification of epidermal growth factor receptor (EGFR) polymorphisms that modify risk for squamous cell carcinoma of the head and neck (HNSCC). Cancer Research. 73: 1340-1340. DOI: 10.1158/1538-7445.Am2013-1340  0.312
2013 Hayes DN, Grandis J, El-Naggar AK. Abstract 1117: Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. Cancer Research. 73: 1117-1117. DOI: 10.1158/1538-7445.Am2013-1117  0.434
2013 Pendleton KP, Lui VW, Lu Y, Gilbert BR, Levine K, Mills GB, Grandis JR. Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A23  0.394
2012 Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (New York, N.Y.). 14: 1005-14. PMID 23226094 DOI: 10.1593/Neo.121212  0.523
2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 8: 1873-4. PMID 22995770 DOI: 10.4161/Auto.22185  0.458
2012 Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biology & Therapy. 13: 1417-24. PMID 22954701 DOI: 10.4161/Cbt.22002  0.495
2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5639-49. PMID 22929803 DOI: 10.1158/1078-0432.Ccr-12-1213  0.489
2012 Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4986-96. PMID 22825581 DOI: 10.1158/1078-0432.Ccr-12-0792  0.531
2012 Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biology & Therapy. 13: 935-45. PMID 22785204 DOI: 10.4161/Cbt.20846  0.779
2012 Lui VW, Grandis JR. Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer. Head and Neck Pathology. S91-7. PMID 22782228 DOI: 10.1007/S12105-012-0364-5  0.317
2012 Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5188-95. PMID 22773520 DOI: 10.1158/1078-0432.Ccr-11-2258  0.418
2012 Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncology. 48: 1136-45. PMID 22732263 DOI: 10.1016/J.Oraloncology.2012.05.015  0.479
2012 Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, ... ... Grandis JR, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discovery. 2: 694-705. PMID 22719020 DOI: 10.1158/2159-8290.Cd-12-0191  0.449
2012 Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, ... Grandis JR, et al. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Research. 72: 3270-81. PMID 22564524 DOI: 10.1158/0008-5472.Can-12-0475-T  0.785
2012 Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics. 11: 1236-46. PMID 22491800 DOI: 10.1158/1535-7163.Mct-11-0936  0.769
2012 Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2850-60. PMID 22490227 DOI: 10.1158/1078-0432.Ccr-11-2486  0.5
2012 Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2278-89. PMID 22351687 DOI: 10.1158/1078-0432.Ccr-11-1593  0.476
2012 Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head & Neck. 34: 1269-76. PMID 22307735 DOI: 10.1002/Hed.21917  0.505
2012 Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respiratory Research. 13: 9. PMID 22296774 DOI: 10.1186/1465-9921-13-9  0.307
2012 Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational New Drugs. 30: 1575-84. PMID 21881918 DOI: 10.1007/S10637-011-9732-3  0.315
2012 Gyanchandani R, Grandis JR, Kim S. Abstract 1380: Mechanisms of resistance to antiangiogenic therapy in preclinical models of head and neck squamous cell carcinoma (HNSCC) Cancer Research. 72: 1380-1380. DOI: 10.1158/1538-7445.Am2012-1380  0.4
2011 Argiris A, Kotsakis AP, Kim S, Worden FP, Savvides P, Gibson MK, Blumenschein GR, Chen HX, Grandis JR, Kies MS. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5564. PMID 28022138 DOI: 10.1200/Jco.2011.29.15_Suppl.5564  0.406
2011 Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology. 47: 961-6. PMID 21889392 DOI: 10.1016/J.Oraloncology.2011.07.034  0.441
2011 Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7248-64. PMID 21868764 DOI: 10.1158/1078-0432.Ccr-11-0690  0.398
2011 Thomas SM, Grandis JR. Targeting mesenchymal exaptation to mitigate tumor growth Cell Cycle. 10: 2626-2627. PMID 21836394 DOI: 10.4161/Cc.10.16.16497  0.411
2011 Langevin SM, Grandis JR, Taioli E. Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk. Cancer Letters. 310: 216-21. PMID 21802839 DOI: 10.1016/J.Canlet.2011.07.007  0.323
2011 Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, ... ... Grandis JR, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, N.Y.). 333: 1157-60. PMID 21798893 DOI: 10.1126/Science.1208130  0.389
2011 Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5935-44. PMID 21791633 DOI: 10.1158/1078-0432.Ccr-11-0370  0.726
2011 Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5513-22. PMID 21737503 DOI: 10.1158/1078-0432.Ccr-11-0086  0.37
2011 Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4996-5004. PMID 21653688 DOI: 10.1158/1078-0432.Ccr-10-3406  0.761
2011 Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4425-38. PMID 21622718 DOI: 10.1158/1078-0432.Ccr-10-3339  0.497
2011 Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Molecular Interventions. 11: 18-26. PMID 21441118 DOI: 10.1124/Mi.11.1.4  0.42
2011 Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer. 117: 1454-62. PMID 21425146 DOI: 10.1002/Cncr.25689  0.335
2011 Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, Lentzsch S, Mapara MY. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cellular Immunology. 268: 37-46. PMID 21376308 DOI: 10.1016/J.Cellimm.2011.01.008  0.344
2011 Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2482-8. PMID 21363880 DOI: 10.1093/Annonc/Mdr002  0.306
2011 Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A. Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head & Neck. 33: 318-23. PMID 21284048 DOI: 10.1002/Hed.21444  0.362
2011 Egloff AM, Grandis JR. Response to combined molecular targeting: defining the role of P-STAT3. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 393-5. PMID 21266530 DOI: 10.1158/1078-0432.Ccr-10-2925  0.437
2011 Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anti-Cancer Drugs. 22: 656-64. PMID 21178766 DOI: 10.1097/Cad.0B013E32834249Ba  0.447
2011 Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prevention Research (Philadelphia, Pa.). 4: 230-7. PMID 21163936 DOI: 10.1158/1940-6207.Capr-10-0249  0.797
2011 Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 154-64. PMID 21062926 DOI: 10.1158/1078-0432.Ccr-10-0992  0.337
2011 Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E. Determinants of head and neck cancer survival by race. Head & Neck. 33: 1092-8. PMID 20967872 DOI: 10.1002/Hed.21584  0.377
2011 Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. American Journal of Clinical Oncology. 34: 372-9. PMID 20859194 DOI: 10.1097/Coc.0B013E3181E84Dc0  0.355
2011 Chai RL, Grandis JR. Biomarkers and Molecular-Targeted Therapeutics in Squamous Cell Carcinoma of the Head and Neck Radiation Medicine Rounds. 2: 307-319. DOI: 10.5003/2151-4208.2.2.307  0.301
2011 Shiwarski D, Bertrand C, Egloff AM, Huang X, Seethala R, Grandis J, Gollin S, Duvvuri U. Abstract LB-220: TMEM16A, a novel calcium-activated chloride channel, modulates tumor proliferation via MAPK and Cyclin-D1 signaling Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-220  0.471
2011 Stransky N, Egloff AM, Tward A, Auclair D, Cibulskis K, Lawrence M, Sivachenko A, Berger M, Seethala R, Sougnez C, Cortes M, Winckler W, Gabriel S, Getz G, Golub T, ... Grandis J, et al. Abstract 3931: Whole genome and whole exome sequencing of head and neck cancer Cancer Research. 71: 3931-3931. DOI: 10.1158/1538-7445.Am2011-3931  0.382
2011 Ahn SM, Kim S, Grandis JR. Epidermal growth factor receptor-targeted therapies Signaling Pathways in Squamous Cancer. 305-333. DOI: 10.1007/978-1-4419-7203-3_15  0.378
2010 Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomarkers : Section a of Disease Markers. 9: 325-39. PMID 22112483 DOI: 10.3233/Cbm-2011-0163  0.462
2010 Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 5294-300. PMID 21079141 DOI: 10.1200/Jco.2010.30.6423  0.377
2010 Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head & Neck. 32: 1412-21. PMID 20848399 DOI: 10.1002/Hed.21365  0.488
2010 Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 29: 5135-45. PMID 20622897 DOI: 10.1038/Onc.2009.279  0.814
2010 Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Davis AG, Bigbee WL, Rom W, Sidransky D. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR Clinical Cancer Research. 16: 3463-3472. PMID 20592015 DOI: 10.1158/1078-0432.Ccr-09-3304  0.301
2010 Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 800-9. PMID 20570883 DOI: 10.1158/1940-6207.Capr-09-0163  0.415
2010 Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. Journal of Proteome Research. 9: 3073-82. PMID 20426488 DOI: 10.1021/Pr901211J  0.825
2010 Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opinion On Investigational Drugs. 19: 709-22. PMID 20415598 DOI: 10.1517/13543781003769844  0.488
2010 Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2489-95. PMID 20406834 DOI: 10.1158/1078-0432.Ccr-09-2318  0.538
2010 Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2571-9. PMID 20388852 DOI: 10.1158/1078-0432.Ccr-10-0333  0.823
2010 Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2427-34. PMID 20371693 DOI: 10.1158/1078-0432.Ccr-09-2658  0.39
2010 Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 31: 864-70. PMID 20197299 DOI: 10.1093/Carcin/Bgq051  0.342
2010 Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biology & Therapy. 9: 1-7. PMID 20038820 DOI: 10.4161/Cbt.9.1.10905  0.425
2010 Kwok J, Langevin SM, Argiris A, Grandis JR, Gooding WE, Taioli E. The impact of health insurance status on the survival of patients with head and neck cancer. Cancer. 116: 476-85. PMID 19937673 DOI: 10.1002/Cncr.24774  0.375
2010 Kotsakis AP, Heron DE, Kubicek GJ, Ferris RL, Kim S, Gibson MK, Duvvuri U, Grandis JR, Johnson JT, Argiris A. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 28: TPS264-TPS264. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps264  0.344
2010 Ferris RL, Kotsakis AP, Heron DE, Kim S, Duvvuri U, Kubicek GJ, Grandis JR, Johnson JT, Argiris A. A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 28: TPS262-TPS262. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps262  0.397
2010 Egloff AM, Lee J, Vaezi AE, Langer CJ, Forastiere AA, Quon H, Burtness B, Grandis JR. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). Journal of Clinical Oncology. 28: 5537-5537. DOI: 10.1200/Jco.2010.28.15_Suppl.5537  0.423
2010 Vaezi AE, Wang X, Buch SC, Farrow D, Weaver DT, D'Andrea AD, Seethala RR, Romkes M, Niedernhofer LJ, Grandis JR. Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer. Journal of Clinical Oncology. 28: 5520-5520. DOI: 10.1200/Jco.2010.28.15_Suppl.5520  0.379
2010 Egloff AM, Kelly L, Panelli M, Davis AG, Siegfried JM, Grandis JR, Argiris A. Abstract 4661: Decreased epidermal growth factor receptor plasma levels as an indicator for head and neck squamous cell carcinoma case status and disease progression Cancer Research. 70: 4661-4661. DOI: 10.1158/1538-7445.Am10-4661  0.405
2010 Wheeler S, Seethala R, Siwak D, Cieply K, Sherer C, Mills G, Grandis JR, Egloff AM. Abstract 4646: Evaluation of EGFR gene amplification status, mRNA, protein, and phosphoprotein levels expression in head and neck cancer patient tissues Cancer Research. 70: 4646-4646. DOI: 10.1158/1538-7445.Am10-4646  0.455
2010 Sen M, Thomas SM, Ly D, Rapireddy S, Grandis JR. Abstract 4139: Development of a transcription factor decoy for efficient systemic administration in head and neck cancer Cancer Research. 70: 4139-4139. DOI: 10.1158/1538-7445.Am10-4139  0.439
2010 Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. Correction: HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer (Clinical Cancer Research (2009) 15, (3740-3750)) Clinical Cancer Research. 16: 4298-4300. DOI: 10.1158/1078-0432.CCR-10-1729  0.708
2010 Razfar A, Grandis JR. Growth factor receptor signaling and metastasis of oral cancer Oral Cancer Metastasis. 185-196. DOI: 10.1007/978-1-4419-0775-2_9  0.337
2009 Gibson MK, Kies M, Kim S, Savvides P, Kotsakis A, Blumenschein G, Worden F, Chen H, Grandis J, Argiris A. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6049. PMID 27961925 DOI: 10.1200/Jco.2009.27.15_Suppl.6049  0.41
2009 Ferris RL, Feinstein T, Grandis J, Johnson R, Branstetter B, Gooding W, Argiris A. Serum biomarkers as predictors of clinical outcome after cetuximab-based therapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6035. PMID 27961910 DOI: 10.1200/Jco.2009.27.15_Suppl.6035  0.373
2009 Egloff A, Feinstein TM, Joyce SC, Kelly LA, Panelli MC, Yang T, Siegfried JM, Grandis JR, Argiris A. Blood biomarker modulation with dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6034. PMID 27961909 DOI: 10.1200/Jco.2009.27.15_Suppl.6034  0.383
2009 Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6529-40. PMID 19825947 DOI: 10.1158/1078-0432.Ccr-09-0862  0.445
2009 Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J. Systematic prediction of human membrane receptor interactions. Proteomics. 9: 5243-55. PMID 19798668 DOI: 10.1002/Pmic.200900259  0.645
2009 Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 30: 1848-56. PMID 19762335 DOI: 10.1093/Carcin/Bgp211  0.783
2009 Thomas SM, Grandis JR. The current state of head and neck cancer gene therapy Human Gene Therapy. 20: 1565-1575. PMID 19747066 DOI: 10.1089/Hum.2009.163  0.396
2009 Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics. 8: 2211-20. PMID 19638453 DOI: 10.1158/1535-7163.Mct-09-0327  0.78
2009 Egloff AM, Grandis JR. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology. 2009: 896407. PMID 19636423 DOI: 10.1155/2009/896407  0.484
2009 Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, Chan AS, Tsang CM, Tsao SW, ... Grandis JR, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. International Journal of Cancer. Journal International Du Cancer. 125: 1884-93. PMID 19588483 DOI: 10.1002/Ijc.24567  0.427
2009 Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3740-50. PMID 19470725 DOI: 10.1158/1078-0432.Ccr-08-3252  0.761
2009 Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, Argiris A, Grandis JR, Lai SY. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. International Journal of Radiation Oncology, Biology, Physics. 75: 1493-500. PMID 19464819 DOI: 10.1016/J.Ijrobp.2008.12.075  0.367
2009 Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene. 28: 2348-57. PMID 19421143 DOI: 10.1038/Onc.2009.108  0.489
2009 Grandis JR, Argiris A. Targeting angiogenesis from premalignancy to metastases. Cancer Prevention Research (Philadelphia, Pa.). 2: 291-4. PMID 19336719 DOI: 10.1158/1940-6207.Capr-09-0032  0.309
2009 López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunology, Immunotherapy : Cii. 58: 1853-64. PMID 19319529 DOI: 10.1007/S00262-009-0697-4  0.414
2009 Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Molecular Pharmacology. 75: 1231-9. PMID 19246337 DOI: 10.1124/Mol.108.052969  0.421
2009 Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, ... ... Grandis JR, et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1235-42. PMID 19204206 DOI: 10.1200/Jco.2008.17.8251  0.49
2009 Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Seminars in Radiation Oncology. 19: 63-8. PMID 19028347 DOI: 10.1016/J.Semradonc.2008.09.009  0.423
2009 Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 425-32. PMID 18832597 DOI: 10.1096/Fj.08-112771  0.493
2009 Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, ... ... Grandis JR, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemotherapy and Pharmacology. 63: 983-95. PMID 18766340 DOI: 10.1007/S00280-008-0823-6  0.446
2009 Cao H, Lin H, Luidens M, Keating T, Grandis J, Davis F. COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry. 9: 203-218. DOI: 10.2174/187152209790773002  0.377
2009 Quesnelle KM, Joyce SC, Grandis JR. Abstract C47: Dual kinase inhibition of EGFR and HER2 can overcome resistance to an EGFR‐targeting agent Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C47  0.77
2009 López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells Cancer Immunology, Immunotherapy. 58: 1863-1864. DOI: 10.1007/s00262-009-0726-3  0.323
2008 Argiris AE, Gibson MK, Heron DE, Smith RP, Ferris RL, Lai SY, Kim SW, Branstetter BF, Johnson JT, Grandis JR. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6002. PMID 27950664 DOI: 10.1200/Jco.2008.26.15_Suppl.6002  0.347
2008 Lai SY, Feinstein TM, Seethala RR, Heron DE, Ferris RL, Grandis JR, Myers EN, Johnson JT, Argiris AE. Prognostic factors in patients with locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy (RT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6045. PMID 27950591 DOI: 10.1200/Jco.2008.26.15_Suppl.6045  0.335
2008 Passero VA, Branstetter BF, Heron DE, Gibson MK, Lai SY, Kim SW, Ferris RL, Grandis JR, Johnson JT, Argiris AE. How to best assess tumor response after curative chemoradiotherapy (CRT) for head and neck squamous cell carcinomas (HNSCC): RECIST or PET/CT? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6023. PMID 27950552 DOI: 10.1200/Jco.2008.26.15_Suppl.6023  0.301
2008 Grandis JR, Lai SY, Esteve FR, Kim SW, Ferris RL, Gibson MK, Johnson R, Heron DE, Johnson JT, Argiris AE. Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6037. PMID 27950535 DOI: 10.1200/Jco.2008.26.15_Suppl.6037  0.453
2008 Gibson MK, Smith RP, Heron DE, Ferris RL, Lai SY, Kim SW, Boyer T, Johnson JT, Grandis JR, Argiris AE. Phase I trial of pemetrexed, cetuximab, and concurrent radiotherapy (RT) in head and neck cancer (HNC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2540. PMID 27947930 DOI: 10.1200/Jco.2008.26.15_Suppl.2540  0.348
2008 Kies MS, Gibson MK, Kim SW, Savvides P, Blumenschein GR, Worden F, Chen H, Grandis JR, Argiris AE. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6072. PMID 27947849 DOI: 10.1200/Jco.2008.26.15_Suppl.6072  0.409
2008 Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Molecular Cancer Research : McR. 6: 1946-56. PMID 19074839 DOI: 10.1158/1541-7786.Mcr-07-2197  0.765
2008 Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7682-90. PMID 19047094 DOI: 10.1158/1078-0432.Ccr-08-1328  0.473
2008 Sok JC, Grandis JR. Genetic screening for oral human papillomavirus infections and cancers of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6723-4. PMID 18980962 DOI: 10.1158/1078-0432.Ccr-08-1915  0.326
2008 Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Experimental Cell Research. 315: 572-82. PMID 18778701 DOI: 10.1016/J.Yexcr.2008.08.009  0.513
2008 Nozawa H, Howell G, Suzuki S, Zhang Q, Qi Y, Klein-Seetharaman J, Wells A, Grandis JR, Thomas SM. Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4336-44. PMID 18594017 DOI: 10.1158/1078-0432.Ccr-07-4857  0.45
2008 Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4284-91. PMID 18594011 DOI: 10.1158/1078-0432.Ccr-07-5226  0.531
2008 Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Molecular Cancer Therapeutics. 7: 1647-55. PMID 18566236 DOI: 10.1158/1535-7163.Mct-07-2444  0.413
2008 Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Seminars in Oncology. 35: 286-97. PMID 18544443 DOI: 10.1053/J.Seminoncol.2008.03.008  0.494
2008 Vokes EE, Cohen EE, Grandis JR. Introduction: head and neck cancer. Seminars in Oncology. 35: 196-7. PMID 18544434 DOI: 10.1053/J.Seminoncol.2008.04.002  0.372
2008 Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY. Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Molecular Cancer Therapeutics. 7: 1355-64. PMID 18524845 DOI: 10.1158/1535-7163.Mct-08-0104  0.452
2008 Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, Cao HJ, Davis PJ, Davis FB. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. Journal of Cellular Biochemistry. 104: 2131-42. PMID 18446786 DOI: 10.1002/Jcb.21772  0.382
2008 Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head & Neck. 30: 667-74. PMID 18383530 DOI: 10.1002/Hed.20859  0.505
2008 Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Molecular Pharmacology. 73: 1632-42. PMID 18326051 DOI: 10.1124/Mol.107.044636  0.836
2008 Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, Grandis JR. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1303-9. PMID 18316548 DOI: 10.1158/1078-0432.Ccr-07-1543  0.431
2008 Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia. 22: 1624-7. PMID 18305561 DOI: 10.1038/Leu.2008.28  0.429
2008 Argiris A, Karamouzis MV, Johnson JT, Heron DE, Myers E, Eibling D, Cano E, Urba S, Gluckman J, Grandis JR, Wang Y, Agarwala SS. Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. The Laryngoscope. 118: 444-9. PMID 18091334 DOI: 10.1097/Mlg.0B013E31815B48F4  0.302
2008 Karamouzis MV, Argiris A, Grandis JR. Clinical applications of gene therapy in head and neck cancer. Current Gene Therapy. 7: 446-57. PMID 18045104 DOI: 10.2174/156652307782793487  0.417
2008 Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Molecular Pharmacology. 73: 627-38. PMID 18025070 DOI: 10.1124/Mol.107.041160  0.488
2008 Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Frontiers in Bioscience : a Journal and Virtual Library. 13: 1857-65. PMID 17981673  0.726
2008 Esteve FR, Stoller RG, Josephson A, Grandis JR, Egorin MJ, Argiris AE. Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies Journal of Clinical Oncology. 26: 14668-14668. DOI: 10.1200/Jco.2008.26.15_Suppl.14668  0.364
2007 Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (New York, N.Y.). 9: 801-11. PMID 17971900 DOI: 10.1593/Neo.07394  0.781
2007 Ferris RL, Grandis JR. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5663-4. PMID 17908953 DOI: 10.1158/1078-0432.Ccr-07-1544  0.407
2007 Grandis JR. Established and emerging concepts in epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, Physics. 69: S22-4. PMID 17848285 DOI: 10.1016/J.Ijrobp.2007.05.040  0.33
2007 Grandis JR, Carbone DP, Rustgi AK. Advances and challenges in aerodigestive epithelial cancer: Meeting summary and research opportunities Cancer Research. 67: 7556-7558. PMID 17686829 DOI: 10.1158/0008-5472.Can-07-1733  0.408
2007 Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. Journal of Cellular Biochemistry. 102: 311-9. PMID 17661350 DOI: 10.1002/Jcb.21475  0.816
2007 Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama. 298: 70-82. PMID 17609492 DOI: 10.1001/Jama.298.1.70  0.473
2007 Nelson EG, Grandis JR. Aberrant kinase signaling: lessons from head and neck cancer. Future Oncology (London, England). 3: 353-61. PMID 17547530 DOI: 10.2217/14796694.3.3.353  0.49
2007 Bigbee WL, Grandis JR, Siegfried JM. Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3107-8. PMID 17545511 DOI: 10.1158/1078-0432.Ccr-07-0746  0.355
2007 Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics. 6: 1414-24. PMID 17431120 DOI: 10.1158/1535-7163.Mct-06-0678  0.772
2007 Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM, Grandis JR, Zhuo J, Yao W, Newton RC, Friedman SM, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1892-902. PMID 17363546 DOI: 10.1158/1078-0432.Ccr-06-2116  0.377
2007 Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Experimental Cell Research. 313: 1361-72. PMID 17349623 DOI: 10.1016/J.Yexcr.2007.01.016  0.451
2007 Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Molecular Pharmacology. 71: 1435-43. PMID 17325127 DOI: 10.1124/Mol.106.032284  0.799
2007 Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head & Neck. 29: 163-88. PMID 17312569 DOI: 10.1002/Hed.20478  0.419
2007 Zhang W, Weissfeld JL, Romkes M, Land SR, Grandis JR, Siegfried JM. Association of the EGFR intron 1 CA repeat length with lung cancer risk. Molecular Carcinogenesis. 46: 372-80. PMID 17219440 DOI: 10.1002/Mc.20285  0.334
2007 Grandis JR. Prognostic biomarkers in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5005-6. PMID 16951212 DOI: 10.1158/1078-0432.Ccr-06-1356  0.424
2007 Lai SY, Lui VW, Koppikar PJ, Thomas SM, Gooding WE, Seethala RR, Branstetter BF, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA in recurrent squamous cell carcinoma of the head and neck (SCCHN): A phase I trial Journal of Clinical Oncology. 25: 6009-6009. DOI: 10.1200/Jco.2007.25.18_Suppl.6009  0.414
2007 Gibson M, Karamouzis M, Smith R, Heron D, Ferris R, Lai S, Kim S, Johnson J, Grandis J, Argiris A. Phase I Trial of Pemetrexed in Combination with Cetuximab and Concurrent Radiotherapy in Head and Neck Cancer (HNC) International Journal of Radiation Oncology*Biology*Physics. 69: S454-S455. DOI: 10.1016/J.Ijrobp.2007.07.1632  0.357
2006 Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Research. 66: 11831-9. PMID 17178880 DOI: 10.1158/0008-5472.Can-06-2876  0.764
2006 Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4675-6. PMID 17028292 DOI: 10.1200/Jco.2006.08.1190  0.467
2006 Egloff AM, Grandis J. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opinion On Therapeutic Targets. 10: 639-47. PMID 16981821 DOI: 10.1517/14728222.10.5.639  0.478
2006 Voynov G, Heron DE, Burton S, Grandis J, Quinn A, Ferris R, Ozhasoglu C, Vogel W, Johnson J. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technology in Cancer Research & Treatment. 5: 529-35. PMID 16981796 DOI: 10.1177/153303460600500510  0.303
2006 Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5064-73. PMID 16951222 DOI: 10.1158/1078-0432.Ccr-06-0913  0.523
2006 Zhou W, Grandis JR, Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. British Journal of Cancer. 95: 164-71. PMID 16804520 DOI: 10.1038/Sj.Bjc.6603234  0.441
2006 Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2666-72. PMID 16763281 DOI: 10.1200/Jco.2005.04.8306  0.512
2006 Elsheikh MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head & Neck. 28: 842-9. PMID 16691557 DOI: 10.1002/Hed.20368  0.323
2006 Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proceedings of the National Academy of Sciences of the United States of America. 103: 6901-6. PMID 16641105 DOI: 10.1073/Pnas.0509719103  0.443
2006 Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opinion On Biological Therapy. 6: 231-41. PMID 16503733 DOI: 10.1517/14712598.6.3.231  0.514
2006 Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. Journal of the National Cancer Institute. 98: 181-9. PMID 16449678 DOI: 10.1093/jnci/djj020  0.307
2006 Chai RL, Grandis JR. Advances in molecular diagnostics and therapeutics in head and neck cancer. Current Treatment Options in Oncology. 7: 3-11. PMID 16343364 DOI: 10.1007/S11864-006-0027-4  0.487
2006 Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head & Neck. 27: 710-7. PMID 15952195 DOI: 10.1002/Hed.20222  0.418
2006 Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM. Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer Journal of Thoracic Oncology. 1: 635-647. DOI: 10.1016/S1556-0864(15)30375-0  0.38
2006 Duvvuri UU, Henson BJ, Huang X, White JS, Parikh RA, Seethala R, Grandis JR, Gollin SM. S038 Characterization of TMEM16A in Squamous Cell Carcinoma of the Head and Neck Archives of Otolaryngology–Head & Neck Surgery. 132: 847. DOI: 10.1001/Archotol.132.8.847-A  0.377
2005 Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochemical Pharmacology. 70: 1685-96. PMID 16207485 DOI: 10.1016/J.Bcp.2005.08.020  0.34
2005 Coppelli FM, Grandis JR. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Current Pharmaceutical Design. 11: 2825-40. PMID 16101440 DOI: 10.2174/1381612054546752  0.362
2005 Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 24: 5897-904. PMID 16007209 DOI: 10.1038/Sj.Onc.1208740  0.492
2005 Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia (New York, N.Y.). 7: 426-31. PMID 15967120 DOI: 10.1593/Neo.04454  0.445
2005 Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 24: 4442-9. PMID 15856028 DOI: 10.1038/Sj.Onc.1208635  0.513
2005 Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, Bigbee WL, Ferris RL. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. The Laryngoscope. 115: 522-7. PMID 15744170 DOI: 10.1097/01.Mlg.0000157850.16649.B8  0.358
2005 Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Research. 65: 1459-70. PMID 15735034 DOI: 10.1158/0008-5472.Can-04-1872  0.473
2005 Riedel F, Götte K, Hörmann K, Grandis JR. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Advances in Oto-Rhino-Laryngology. 62: 103-20. PMID 15608422 DOI: 10.1159/000082500  0.388
2005 Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Seminars in Oncology. 31: 734-43. PMID 15599851 DOI: 10.1053/J.Seminoncol.2004.09.015  0.515
2005 Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy Oncogene. 24: 970-979. PMID 15592503 DOI: 10.1038/Sj.Onc.1208316  0.465
2005 Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head & Neck. 26: 870-7. PMID 15390206 DOI: 10.1002/Hed.20029  0.387
2005 Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erratum: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma Oncogene. 24: 8216-8216. DOI: 10.1038/Sj.Onc.1209224  0.432
2004 Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S. Head and neck cancer: meeting summary and research opportunities. Cancer Research. 64: 8126-9. PMID 15520225 DOI: 10.1158/0008-5472.Can-04-2445  0.403
2004 Thomas SM, Zeng Q, Epperly MW, Gooding WE, Pastan I, Wang QC, Greenberger J, Grandis JR. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7079-87. PMID 15501988 DOI: 10.1158/1078-0432.Ccr-04-0587  0.376
2004 Gorelik E, Edwards RP, Feng X, Marrangoni AM, Grandis JR, Drenning SD, Velikokhatnaya L, Kwon JA, Lokshin AE. IL-12 receptor-mediated upregulation of FasL in human ovarian carcinoma cells International Journal of Cancer. 112: 620-627. PMID 15382042 DOI: 10.1002/Ijc.20482  0.329
2004 Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5930-9. PMID 15355926 DOI: 10.1158/1078-0432.Ccr-03-0677  0.516
2004 Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Research. 64: 6166-73. PMID 15342401 DOI: 10.1158/0008-5472.Can-04-0504  0.441
2004 Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation Cancer Treatment Reviews. 30: 255-268. PMID 15059649 DOI: 10.1016/J.Ctrv.2003.10.003  0.429
2004 Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacology & Therapeutics. 102: 37-46. PMID 15056497 DOI: 10.1016/J.Pharmthera.2004.01.002  0.497
2004 Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5028-35. PMID 14581378  0.398
2003 Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4205-13. PMID 14519647  0.349
2003 Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Research. 63: 5629-35. PMID 14500405  0.42
2003 Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, Grandis JR. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene. 22: 6183-93. PMID 13679857 DOI: 10.1038/Sj.Onc.1206720  0.485
2003 Lui VW, Wentzel AL, Xiao D, Lew KL, Singh SV, Grandis JR. Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. Carcinogenesis. 24: 1705-12. PMID 12896907 DOI: 10.1093/Carcin/Bgg127  0.403
2003 Wells A, Grandis JR. Phospholipase C-gamma1 in tumor progression. Clinical & Experimental Metastasis. 20: 285-90. PMID 12856715 DOI: 10.1023/A:1024088922957  0.369
2003 Thomas SM, Zeng Q, Dyer KF, Suscovich TJ, Kanter PM, Whalen JD, Watkins SF, Grandis JR. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Therapy. 10: 518-28. PMID 12833132 DOI: 10.1038/Sj.Cgt.7700567  0.316
2003 Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Review of Anticancer Therapy. 3: 367-80. PMID 12820779 DOI: 10.1586/14737140.3.3.367  0.474
2003 Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene. 22: 3608-15. PMID 12789269 DOI: 10.1038/Sj.Onc.1206523  0.431
2003 Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J, Grandis JR. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. The Journal of Biological Chemistry. 278: 31574-83. PMID 12771142 DOI: 10.1074/Jbc.M303499200  0.498
2003 Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proceedings of the National Academy of Sciences of the United States of America. 100: 4138-43. PMID 12640143 DOI: 10.1073/Pnas.0534764100  0.458
2003 Miranda MB, Dyer KF, Grandis JR, Johnson DE. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia. 17: 390-400. PMID 12592339 DOI: 10.1038/Sj.Leu.2402779  0.31
2003 Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Current Oncology Reports. 5: 140-6. PMID 12583831 DOI: 10.1007/S11912-003-0101-Z  0.522
2003 Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma Journal of Dental Research. 82: 11-16. PMID 12508038 DOI: 10.1177/154405910308200104  0.401
2003 Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer Head and Neck. 25: 67-73. PMID 12478546 DOI: 10.1002/Hed.10224  0.502
2003 Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3570-8. PMID 12429648  0.312
2003 Riedel F, Götte K, Li M, Hörmann K, Grandis JR. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo International Journal of Oncology. 23: 577-583. DOI: 10.3892/Ijo.23.3.577  0.392
2002 Zeng Q, Kanter PM, Dhir R, Gooding WE, Huang L, Grandis JR. Lack of toxicity of EGFR antisense gene therapy. Journal of Experimental Therapeutics & Oncology. 2: 174-86. PMID 12415634 DOI: 10.1046/J.1359-4117.2002.01033.X  0.488
2002 Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 13: 355-62. PMID 12193474  0.408
2002 Riedel F, Götte K, Li M, Hörmann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. International Journal of Oncology. 21: 11-6. PMID 12063543  0.371
2002 Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Research. 22: 1-11. PMID 12017269  0.343
2002 Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. The Prostate. 51: 241-6. PMID 11987152 DOI: 10.1002/Pros.10079  0.338
2002 Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, Grandis JR. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene. 21: 2846-53. PMID 11973644 DOI: 10.1038/Sj.Onc.1205385  0.492
2002 Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. Journal of the National Cancer Institute. 94: 375-83. PMID 11880476 DOI: 10.1093/Jnci/94.5.375  0.432
2002 Riedel F, Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. International Journal of Oncology. 21: 11-16. DOI: 10.3892/Ijo.21.1.11  0.474
2002 Ni Z, Lou W, Lee SO, Dhir R, De Miguel F, Grandis JR, Gao AC. Selective Activation Of Members Of The Signal Transducers And Activators Of Transcription Family In Prostate Carcinoma Journal of Urology. 167: 1859-1862. DOI: 10.1016/S0022-5347(05)65249-4  0.319
2001 Lango MN, Shin DM, Grandis JR. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Current Opinion in Oncology. 13: 168-75. PMID 11307060 DOI: 10.1097/00001622-200105000-00007  0.511
2000 Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 19: 2489-95. PMID 10851047 DOI: 10.1038/Sj.Onc.1203483  0.499
2000 Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope. 110: 868-874. PMID 10807365 DOI: 10.1097/00005537-200005000-00016  0.527
2000 Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America. 97: 4227-32. PMID 10760290 DOI: 10.1073/Pnas.97.8.4227  0.514
1998 Runge D, Runge DM, Drenning SD, Bowen WC, Grandis JR, Michalopoulos GK. Growth and differentiation of rat hepatocytes: changes in transcription factors HNF-3, HNF-4, STAT-3, and STAT-5. Biochemical and Biophysical Research Communications. 250: 762-8. PMID 9784420 DOI: 10.1006/Bbrc.1998.9384  0.3
1998 Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. The Journal of Clinical Investigation. 102: 1385-92. PMID 9769331 DOI: 10.1172/Jci3785  0.425
1998 He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. Journal of the National Cancer Institute. 90: 1080-7. PMID 9672256 DOI: 10.1093/jnci/90.14.1080  0.378
1998 Grandis JR, Zeng Q, Drenning SD, Tweardy DJ. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. International Journal of Oncology. 13: 375-8. PMID 9664135 DOI: 10.3892/Ijo.13.2.375  0.384
1998 Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Journal of Cellular Biochemistry. 69: 55-62. PMID 9513046 DOI: 10.1002/(Sici)1097-4644(19980401)69:1<55::Aid-Jcb6>3.0.Co;2-U  0.399
1997 Grandis JR, Perez-Perez GI, Yu VL, Johnson JT, Blaser MJ. Lack of serologic evidence for Helicobacter pylori infection in head and neck cancer Head and Neck. 19: 216-218. PMID 9142522 DOI: 10.1002/(Sici)1097-0347(199705)19:3<216::Aid-Hed9>3.0.Co;2-5  0.327
1995 Grandis JR, Chang MJ, Yu WD, Johnson CS. Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system. Archives of Otolaryngology--Head & Neck Surgery. 121: 197-200. PMID 7840928 DOI: 10.1001/Archotol.1995.01890020059012  0.345
1995 Grandis JR, Johnson JT. Antibiotics in head and neck oncology Current Opinion in Otolaryngology & Head and Neck Surgery. 3: 84-88. DOI: 10.1097/00020840-199504000-00003  0.327
1993 Grandis JR, Hirsch BE, Yu VL. Simultaneous presentation of malignant external otitis and temporal bone cancer. Archives of Otolaryngology--Head & Neck Surgery. 119: 687-9. PMID 8499104 DOI: 10.1001/Archotol.1993.01880180107021  0.315
1993 Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. Journal of Cellular Biochemistry. Supplement. 188-91. PMID 8412192 DOI: 10.1002/Jcb.240531027  0.432
1992 Grandis JR, Tweardy DJ. The Role Of Peptide Growth Factors In Head And Neck Carcinoma Otolaryngologic Clinics of North America. 25: 1105-1115. DOI: 10.1016/S0030-6665(20)30928-2  0.405
Show low-probability matches.